Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The American Association for Cancer Research (AACR) and the Rivkin Center for Ovarian Cancer. The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) activities for physicians.
CREDIT DESIGNATION STATEMENT
AACR has designated this live activity for a maximum of 16.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
CLAIMING (CME) CREDIT
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Monday, November 9, 2020. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the 12th Biennial Ovarian Cancer Research Symposium website or via email. Your CME certificate will be sent to you via email after the completion of the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
STATEMENT OF EDUCATIONAL NEED, TARGET AUDIENCE, AND LEARNING OBJECTIVES
Approximately 22,000 women in the United States are diagnosed with ovarian cancer every year. The overall 5-year survival rate is only 46% for ovarian cancer, and the rate is markedly lower for advanced stage cancers. Sadly, the survival rates have only improved slightly over 40 years. While ovarian cancer is the most deadly gynecologic cancer, it is underrepresented in both research funding and research participants. Additionally complicating the difficulty in diagnosing the disease beyond its physical complexities is that ovarian cancer is a rare disease and many providers will have limited access to information on the signs, symptoms, and latest techniques to diagnose the disease.
In this course we are addressing major needs in ovarian cancer care and research by educating health care providers and researchers in the latest research on improving treatment, early detection, and prevention, as well as promoting a better understanding of the many diseases under the umbrella of ovarian cancer.
- Attendees will need access to and updates on the most recent research in a wide array of topics including novel treatment methods, best early detection techniques, basic biology and categorization of the disease, and recent data on risk, prevention, and progression of ovarian cancer.
- Attendees will need information on recent trends in specialized fields such as cancer control strategies and immunotherapy to understand the continuum between prevention and cure.
- Attendees will need opportunities to network with other experts in the field to initiate collaborations in research and in clinical care.
The Planning Committee has designed this event to benefit the following audiences: basic scientists, epidemiologists, clinical scientists, and clinicians as well as geneticists, public health researchers, nurses, and advocates for ovarian cancer research. This conference encourages the collaboration between professionals with a wide variety of expertise including: gynecologic oncology, medical oncology, pathology, genetics, molecular biology, cell biology, public health, behavioral epidemiology, translational research, patient care, and patient advocacy.
After participating in this CME activity, physicians should be able to:
- Define cancer control strategies to detect ovarian cancer at the earliest stages and to prevent the disease
- Identify model systems that best recapitulate ovarian cancer
- Distinguish the clinical and biological considerations of rare subtypes of ovarian cancer
- Articulate how DNA Repair and other molecular mechanisms impact ovarian cancer development and treatment
- Explain the elements of tumor microenvironment and immunology as they contribute to ovarian cancer growth and as possible targets for treatment
- Identify novel therapies against ovarian cancer and assess the response and resistance of new therapies
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
ACKNOWLEDGMENT OF FINANCIAL OR OTHER SUPPORT
This activity is supported by Professional Educational Grants which will be disclosed at the activity.
QUESTIONS ABOUT CME?
Please contact the Office of CME at (215) 440-9300 or [email protected].